We are live on ! Find out more

Whitehawk Therapeutics

WHWK

Market cap $188M

3.30 USD

-0.16

4.62%

At close Updated Oct 29, 4:00 PM EDT

1 day

-4.62%

5 days

2.17%

1 month

-11.53%

3 months

-9.84%

6 months

-18.32%

Year to date

35.25%

1 year

34.15%

5 years

-87.77%

10 years

-94.36%

About: Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Employees: 23

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 75%

Negative 0%

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings High MUC16 Expression Was Associated with Poor Real-World Overall Survival in High-Grade Serous Ovarian Carcinoma, the Most Common Subtype of Ovarian Cancer Findings Reinforce the Scientific Rationale for HWK-016, Whitehawk's Next-Generation MUC16-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Oct. 1, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting mucin 16 (MUC16) as a durable therapeutic target and potential prognostic biomarker in ovarian cancer.

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Development MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC).

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., Sept. 10, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

MORRISTOWN, N.J., Sept. 2, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences: Cantor Global Healthcare Conference 2026 – management will participate in investor meetings on September 9, 2026.

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

The mean of analysts' price targets for Whitehawk Therapeutics, Inc. (WHWK) points to a 47.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028 MORRISTOWN, N.J., Aug. 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights.

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

BOSTON & MORRISTOWN, N.J.--(BUSINESS WIRE)-- #ADC--Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resultin.

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026 MORRISTOWN, N.J., May 30, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure related homolog protein 6 (SEZ6) with a next-generation ADC for the treatment of neuroendocrine tumors, including small cell lung cancer (SCLC).

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

See News Rankings

Price charts implemented using Lightweight Charts™